

**List of WHO-Listed Authorities (WLA)  
(in alphabetical order) as of October 2023**

Country	Regulatory Authority (RA)	Link to the RA and contact point	Listed product stream(s)	Listed function(s)*	Date of first listing	Date of renewal	Link to the listing summary
Republic of Korea	Ministry of Food and Drug Safety (MFDS)	<ul style="list-style-type: none"> <li>▪ Please click <a href="#">HERE</a> to access the website of the regulatory authority</li> <li>▪ Contact point: <a href="mailto:intlpharm@korea.kr">intlpharm@korea.kr</a></li> </ul>	<b>Medicines</b> (including multisource [generics], and new medicines [new chemical entities], biotherapeutics and similar biotherapeutic products)	<ol style="list-style-type: none"> <li>1. Vigilance</li> <li>2. Market surveillance and control</li> <li>3. Licensing establishments</li> <li>4. Regulatory inspection (GMP and GSDP)</li> <li>5. Laboratory testing</li> <li>6. Clinical trials oversight</li> </ol>	26 October 2023	5 years from date of initial listing	TBC
Republic of Korea	Ministry of Food and Drug Safety (MFDS)	<ul style="list-style-type: none"> <li>▪ Please click <a href="#">HERE</a> to access the website of the regulatory authority</li> <li>▪ Contact point: <a href="mailto:intlpharm@korea.kr">intlpharm@korea.kr</a></li> </ul>	<b>Vaccines</b>	<ol style="list-style-type: none"> <li>1. Registration and marketing authorization</li> <li>2. Vigilance</li> <li>3. Market surveillance and control</li> <li>4. Licensing establishments</li> <li>5. Regulatory inspection (GMP and GSDP)</li> <li>6. Laboratory testing</li> <li>7. Clinical trials oversight</li> <li>8. NRA lot Release</li> </ol>	26 October 2023	5 years from date of initial listing	TBC
Singapore	Health Sciences Authority (HSA)	<ul style="list-style-type: none"> <li>▪ Please click <a href="#">HERE</a> to access the website of the regulatory authority</li> <li>▪ Contact point: <a href="mailto:hsa_intl_office@hsa.gov.sg">hsa_intl_office@hsa.gov.sg</a></li> </ul>	<b>Medicines</b> (including multisource [generics], and new medicines [new chemical entities], biotherapeutics and similar biotherapeutic products)	<ol style="list-style-type: none"> <li>1. Registration and marketing authorization</li> <li>2. Vigilance</li> <li>3. Licensing establishments</li> <li>4. Regulatory inspection (GMP, GSDP and GCP)</li> <li>5. Laboratory testing</li> <li>6. Clinical trials oversight</li> </ol>	26 October 2023	5 years from date of initial listing	TBC

Switzerland	Swissmedic	<ul style="list-style-type: none"> <li>▪ Please click <a href="#">HERE</a> to access the website of the regulatory authority</li> <li>▪ Contact point: <a href="mailto:Networking@swissmedic.ch">Networking@swissmedic.ch</a></li> </ul>	<b>Medicines</b> (including multisource [generics], and new medicines [new chemical entities], biotherapeutics and similar biotherapeutic products)	<ol style="list-style-type: none"> <li>1. Registration and marketing authorization</li> <li>2. Vigilance</li> <li>3. Market surveillance and control</li> <li>4. Licensing establishments</li> <li>5. Regulatory inspection (GMP, GSDP and GCP)</li> <li>6. Laboratory testing</li> <li>7. Clinical trials oversight</li> </ol>	26 October 2023	5 years from date of initial listing	TBC
Switzerland	Swissmedic	<ul style="list-style-type: none"> <li>▪ Please click <a href="#">HERE</a> to access the website of the regulatory authority</li> <li>▪ Contact point: <a href="mailto:Networking@swissmedic.ch">Networking@swissmedic.ch</a></li> </ul>	<b>Vaccines</b>	<ol style="list-style-type: none"> <li>1. Registration and marketing authorization</li> <li>2. Vigilance</li> <li>3. Market surveillance and control</li> <li>4. Licensing establishments</li> <li>5. Regulatory inspection (GMP, GSDP and GCP)</li> <li>6. Laboratory testing</li> <li>7. Clinical trials oversight</li> <li>8. NRA lot release</li> </ol>	26 October 2023	5 years from date of initial listing	TBC

\* Evaluation of the regulatory system is always performed in conjunction with the function(s) for which listing is sought